2024
DOI: 10.1016/j.ijpx.2024.100229
|View full text |Cite
|
Sign up to set email alerts
|

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers

Eva Dokoupilová,
David Vetchý,
Sylvie Pavloková
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 45 publications
(54 reference statements)
0
1
0
Order By: Relevance
“…Subsequently, a study examined the impact of different treatments on SARS-CoV-2 antibody levels in patients with autoimmune rheumatic disease undergoing Pfizer/BioNTech mRNA vaccination [177]. Original adalimumab treatment resulted in stable antibody levels, whereas biosimilar adalimumab showed a significant decrease [177].…”
Section: Vaccine Development and Challengesmentioning
confidence: 99%
“…Subsequently, a study examined the impact of different treatments on SARS-CoV-2 antibody levels in patients with autoimmune rheumatic disease undergoing Pfizer/BioNTech mRNA vaccination [177]. Original adalimumab treatment resulted in stable antibody levels, whereas biosimilar adalimumab showed a significant decrease [177].…”
Section: Vaccine Development and Challengesmentioning
confidence: 99%